Aduro Biotech patient develops listeriosis By: MarketMinute.com Stock News November 24, 2015 at 12:04 PM EST A patient being treated with Aduro Biotech's (Nasdaq: ADRO) CRS-207 developed listeriosis. The stock price plunged $5.09 to $27.14. Related Stocks: Aduro Biotech